Compounded GLP‑1 risks

Compounded versions of popular weight-loss shots are still being sold across the U.S. even after federal shortages ended, and researchers found signs of sterility and ingredient problems. (healio.com; fda.gov) GLP-1 drugs such as semaglutide and tirzepatide are injectable medicines used for diabetes and obesity, and compounding means mixing or altering ingredients to make a patient-specific version when a standard product cannot meet a medical need. The Food and Drug Administration says compounded drugs are not FDA-approved and are not reviewed in advance for safety, effectiveness, or quality. (fda.gov; ajmc.com) In a secret-shopper study presented at the Obesity Medicine Association meeting in San Diego on April 10-12, 2026, University of Colorado researcher Michael DiStefano and colleagues called 74 weight-loss clinics and medical spas in two states while posing as customers. They found 69 of 74 offered compounded semaglutide and 65 of 74 offered compounded tirzepatide. (healio.com; medscape.com) About 60% of the businesses in that study said their products included additives such as glycine, levocarnitine, or B vitamins. The researchers also said several supplier facilities showed inconsistent sterile-compounding licenses or prior Food and Drug Administration or state board actions. (healio.com; medscape.com) Federal policy changed after the branded supply picture improved. The FDA said tirzepatide shortage-related enforcement discretion for many compounders ended in March 2025, and semaglutide enforcement discretion ended for state-licensed pharmacies in April 2025 and for outsourcing facilities in May 2025. (fda.gov; fda.gov; fda.gov) That left a narrower lane for legal compounding: patient-specific medical need or a genuine shortage. In a February 6, 2026 statement, FDA Commissioner Martin Makary said the agency would move against non-approved compounded GLP-1 products being mass-marketed as alternatives to approved drugs. (fda.gov; ajmc.com) The agency said marketers cannot call compounded GLP-1s “generic” versions, say they use the same active ingredient as approved drugs, or promise the same results. FDA said companies that do not correct violations could face seizure or injunction. (fda.gov; ajmc.com) FDA has also warned about handling and shipping. Injectable GLP-1 products need refrigeration, and the agency says some compounded shipments arrived warm or with inadequate ice packs, which can affect drug quality. (fda.gov; ajmc.com) Patients still seek compounded products because branded drugs can be expensive and insurance coverage is uneven, even after supply has improved. FDA says patients who need these medicines should use a clinician’s prescription and a state-licensed pharmacy, not marketing claims on social media or telehealth ads. (ajmc.com; fda.gov) The market that grew during the 2022-2025 shortages has not disappeared; it is being pushed into a tighter legal and regulatory box. For patients, the practical question is no longer only whether they can find a GLP-1 shot, but whether the version being sold is approved, properly handled, and traceable. (healio.com; fda.gov; fda.gov)